We are live on ! Find out more
IBO

Impact BioMedical
IBO

22 hedge funds and large institutions have $1.76M invested in Impact BioMedical in 2026 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 4 increasing their positions, 5 reducing their positions, and 0 closing their positions.

New
Increased
Maintained
Reduced
Closed

10% more funds holding

Funds holding: 20 → 22 (+2)

20% less repeat investments, than reductions

Existing positions increased: 4 | Existing positions reduced: 5

21% less capital invested

Capital invested by funds: $2.23M → $1.76M (-$470K)

26.99% less ownership

Funds ownership: 30.55% → 3.56% (-27%)

Holders
22
Holders Change
+2
Holders Change %
+10%
% of All Funds
0.26%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
3
Increased
4
Reduced
5
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Vanguard Capital Management
Vanguard Capital Management
Pennsylvania
+$59.5K
2
Citadel Advisors
Citadel Advisors
Florida
+$29.3K
3
Jane Street
Jane Street
New York
+$14.5K
4
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust
Pennsylvania
+$2.5K
5
Morgan Stanley
Morgan Stanley
New York
+$7

Top Sellers

Rank Fund Capital Flow
1
UBS Group
UBS Group
Switzerland
-$17.8K
2
Two Sigma Investments
Two Sigma Investments
New York
-$12K
3
Northern Trust
Northern Trust
Illinois
-$5.01K
4
Geode Capital Management
Geode Capital Management
Massachusetts
-$4.59K
5
Citigroup
Citigroup
New York
-$208

IBO Hedge Fund Activity: Q2 2026 in Review

22 of the 8,318 institutional investors tracked by Wall St. Rank reported a position in Impact BioMedical (IBO) for Q2 2026, worth a combined $1.76M — down 21% from $2.23M a quarter earlier.

Buyers outnumbered sellers: 3 funds opened new IBO positions and 0 closed out — a net gain of 3 holders — while 4 added to existing stakes and 5 trimmed.

The largest buyer was Vanguard Capital Management, adding an estimated $59.5K. The largest seller was UBS Group, cutting an estimated $17.8K.

  • 22 institutional investors held Impact BioMedical (IBO) as of Q2 2026, up from 20 in Q1 2026.
  • Funds reported $1.76M of Impact BioMedical stock for Q2 2026, down 21% quarter-over-quarter.
  • 3 funds opened new Impact BioMedical positions in Q2 2026 and 0 closed out, a net change of +3 holders.
  • The largest Impact BioMedical buyer in Q2 2026 was Vanguard Capital Management, an estimated $59.5K added.
  • The largest Impact BioMedical seller in Q2 2026 was UBS Group, an estimated $17.8K sold.

Based on aggregated 13F filings for Q2 2026.